Project Grant K01AI180591
Award Date
7/18/24
Completion Date
6/30/29
Dollars Obligated
$135K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Torrance, CA 90502, USA
Similar Awards
This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to discover and develop new, more potent antifungal therapies for treating invasive fungal infections such as cryptococcosis, candidiasis, and aspergillosis. The funding will support the continued screening of chemical libraries to identify lead compounds that selectively inhibit the fungal ceramide synthase 1...
This $233,670 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to determine the genetic mechanisms underlying skin colonization by the emerging fungal pathogen Candida auris. The University of Michigan, the awardee, will leverage its established in vitro and in vivo models to investigate clade-specific differences in C. auris adhesion and skin...
This $709,239 federal Project Grant award, provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to understand the mechanisms underlying Candida auris skin colonization. The funded project, led by researchers at the University of California, San Francisco, aims to: 1) identify C. auris factors that enable hair binding and skin colonization, 2)...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $822,646 to support research into the mechanisms driving synergistic lethality in polymicrobial fungal-bacterial infections. The project aims to investigate how the fungal pathogen Candida albicans interacts with the bacterial pathogen Staphylococcus aureus to increase toxin production, dysregulate host immune and...
This $416,396 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), to The Methodist Hospital Research Institute (HMRI) in Houston, Texas. The purpose of the grant is to advance the development of natural phenolic compounds, specifically caffeic acid phenethyl ester (CAPE) and ellagic acid (EA), for the management of oral candidiasis, an opportunistic fungal infection that commonly...
This federal Project Grant award of $857,215 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to investigate how the fungal pathogen Candida albicans adapts its acetylome, or acetylation patterns, to survive in different host environments during oral and invasive infections. The research aims to identify C. albicans GCN5 (a lysine acetyltransferase) target proteins that are acetylated...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $642,775 to the University of California, Davis to accelerate the discovery of new antifungal peptides. The research will leverage the university's one-bead one-compound (OBOC) combinatorial technology and screening strategies to rapidly identify and optimize novel antifungal agents with desired physiochemical...
The University of Southern California (USC) received a $623,986 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The funding supports a research project to study the genetic and molecular mechanisms that enable fungi, specifically the opportunistic pathogen Saccharomyces cerevisiae, to persist and cause infections in mammalian hosts. Key objectives include: Identifying causal...
This Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development of novel antifungal therapeutics targeting the glycosylphosphatidylinositol (GPI) biosynthesis pathway. The $170,000 award to Prokaryotics Incorporated will fund structural biology studies to elucidate the molecular interactions between the natural product M743 and the fungal GPI biosynthesis...
This $300,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research program aims to develop an anti-Candida peptide vaccine. The goal is to create a vaccine that can be used alone or as an adjunct to antifungal drugs to reduce fungal burden and morbidity due to life-threatening disseminated candidiasis, a common bloodstream infection in hospitalized patients. The project will utilize a novel...